How did Metir plc (LSE:MET), a small AIM-quoted water-monitoring business, move from a brief share suspension in July 2026 to a run of commercial announcements over the summer? The answer lies in its delayed 2025 accounts, a restoration of trading and a set of product updates that the company says are building its sales pipeline.

What Metir Does

Metir describes itself as a provider of fast-response, mobile and point-of-use water and environmental monitoring technologies, headquartered in York. The company was formerly known as Microsaic Systems and rebranded as Metir in February 2025. According to its final results, it operates through two divisions. Modern Water supplies Microtox® toxicity testing instruments and reagents, while Microsaic Systems focuses on detection of PFAS, the so-called forever chemicals. The group also sells QuickChek® sulphate reducing bacteria kits and is developing a pathogen detector.

Suspension, Results and Restoration

On 1 July 2026, trading in Metir's ordinary shares on AIM was temporarily suspended at the company's request, pending publication of its annual audited accounts. On 7 July 2026, Metir published final results for the year ended 31 December 2025, and trading was restored the same day. The notice of Annual General Meeting and posting of the 2025 Annual Report followed on 8 July, and its AGM result was announced on 6 August 2026.

The results showed Revenue of £1.44 million, up from £0.23 million in 2024. The group reported a Gross Profit of £0.56 million, compared with a gross loss of £0.13 million a year earlier, and its loss before tax narrowed to £0.87 million from £1.70 million. Cash and equivalents stood at £1.06 million at the year end, against £0.19 million a year before. Metir raised £0.85 million gross in June 2025 and £1.0 million before expenses in December 2025.

Qatar Project and Summer Updates

On 23 July 2026, Metir said its Modern Water division had received a Project Confirmation Letter from Avanceon covering its continuous toxicity monitoring deployment in Qatar for Kahramaa. The company said an outstanding milestone payment of approximately £161,000 and a performance payment of about £44,000 were involved, and that it expects recurring consumables revenue of around £30,000 a month from 27 installed systems. Phase 1 handover was reset to October 2026. Metir said reagent handling in high ambient temperatures had caused issues, which it is addressing with improved storage and a local laboratory in Doha.

In a product development and commercial update dated 4 August 2026, the company reported 19 Microtox® LX systems sold in 2026 and 144 customer quotations issued during the year. It said more than 20,500 QuickChek® SRB kits had been quoted, with deliveries from restarted run-in production expected in October 2026. It also reported validation of its PFAS platform with ProDecon Services and progress with Aptamer Group on a Cryptosporidium detector, with commercial rollout planned for the first half of 2027.

Risks to Consider

The board stated in its results that there is a material uncertainty relating to future fundraising, although it expects the company to remain solvent for at least 12 months with minimum additional funding of £0.50 million. Quotations and memoranda of understanding, including a strategic MOU with Portsmouth Aviation signed on 17 July, do not guarantee orders. The Qatar timetable has already moved, and the company remains loss-making, so further dilution from Equity raises may be possible.

Conclusion

Metir's shares were suspended because its audited 2025 accounts were not published in time, and trading resumed once final results appeared on 7 July 2026. Since then, the company has highlighted Qatar payments, instrument sales and product milestones. Its reported figures show faster revenue growth and a narrower loss, but its Going Concern disclosure indicates that funding remains a central issue to watch.